A literature review of AI/ML in drug discovery, with a case study summarizing network pharmacology and machine learning based target and hit discoveries for gout-related diseases.
TransDiffSBDD: Causality-Aware Multi-Modal Structure-Based Drug Design
1 Pith paper cite this work. Polarity classification is still indexing.
abstract
Structure-based drug design (SBDD) is a critical task in drug discovery, requiring the generation of molecular information across two distinct modalities: discrete molecular graphs and continuous 3D coordinates. However, existing SBDD methods often overlook two key challenges: (1) the multi-modal nature of this task and (2) the causal relationship between these modalities, limiting their plausibility and performance. To address both challenges, we propose TransDiffSBDD, an integrated framework combining autoregressive transformers and diffusion models for SBDD. Specifically, the autoregressive transformer models discrete molecular information, while the diffusion model samples continuous distributions, effectively resolving the first challenge. To address the second challenge, we design a hybrid-modal sequence for protein-ligand complexes that explicitly respects the causality between modalities. Experiments on the CrossDocked2020 benchmark demonstrate that TransDiffSBDD outperforms existing baselines.
fields
cs.AI 1years
2025 1verdicts
UNVERDICTED 1representative citing papers
citing papers explorer
-
Artificial intelligence in drug discovery: A comprehensive review with a case study on hyperuricemia, gout arthritis, and hyperuricemic nephropathy
A literature review of AI/ML in drug discovery, with a case study summarizing network pharmacology and machine learning based target and hit discoveries for gout-related diseases.